- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02557568
Evaluation of an Algorithm for Identifying Persistent Nasal Staphylococcus Aureus Carriage in a Cohort of Healthy Volunteers and Patients Regularly Monitored at the CHU of Saint-Etienne (ScreenStaph)
The nasal carriage of Staphylococcus aureus is a major risk factor of S. aureus infection, notably in hemodialysis patients (HPs). Decolonization strategies were shown able to reduce the rate of S. aureus infection in this category of patients although the risk of emergence of antimicrobial resistance persists. Approximately one quarter of the general population is colonized by S. aureus in the anterior part of the nostril (vestibulum nasi). Three main categories of nasal carriers have been historically identified: persistent carriers (20%, 12-30%]), intermittent carriers (30%, [16-70%]) and non-carriers (50% [16-69%]). By contrast to intermittent carriers and non-carriers, persistent nasal carriers have a higher risk of S. aureus infection, especially in continuous peritoneal dialysis and in orthopedic surgery.
Persistent carriers are characterized by a higher nasal bacterial load, a longer duration of carriage, a lower rate of exchange of S. aureus strains, and a particular affinity for the carried strain. However, there is no consensual definition of this persistent carriage state. In previous studies, 5 to 12 nasal sampling episodes were realized for a period ranging from 5 weeks to 8 years. The index of carriage, corresponding to the number of samples positive for S. aureus divided by the total number of samples, has been proposed to standardize the definition of the carriage state. According to standard tools, it is almost impossible to determine the nasal carriage state in routine practice.
Recently, an algorithm based on one or two quantitative cultures from nasal samples taken within 2 days that was able to distinguish accurately persistent and non-persistent nasal carriers of S. aureus has been described; only one nasal sample was needed in more than 9 cases out of 10. The aim of the present study was to assess prospectively the reliability of this algorithm in clinical practice in a cohort of healthcare workers (HCWs) and HPs and to check its ability for identifying patients with the highest risk of S. aureus infection
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Saint-Etienne, France, 42055
- CHU Saint-Etienne
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy Volunteers or hemodialysis patients
- carrier state of S. aureus unknown
- written consent
Exclusion Criteria:
- chronic soft skin tissue infection due to S. aureus or eczema,
- ongoing or completed antibiotic treatment for less than 15 days,
- nasal decolonization by mupirocin or skin decolonization by antiseptic bath for at least 5 consecutive days in the previous year,
- pregnancy,
- HIV infection
- hemostasis disorder.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Hemodialysis patients (HPs)
staphylococcus aureus carriage is measured in nose
|
Staphylococcus aureus carriage is measured in the nose.
Nasal samples were taken by the nursing staff of the ward using nylon flocked swab.
Prior taking the sample, swabs were wetted using an additional tube containing a sponge impregnated with normal saline solution.
|
Experimental: Healthcare Workers (HCWs)
staphylococcus aureus carriage is measured in nose
|
Staphylococcus aureus carriage is measured in the nose.
Nasal samples were taken by the nursing staff of the ward using nylon flocked swab.
Prior taking the sample, swabs were wetted using an additional tube containing a sponge impregnated with normal saline solution.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
S. aureus nasal carriage state
Time Frame: 10-week period
|
HPs and HCWs were sampled over a 10-week period using at least 7 and at most 12 sampling episodes.
S. aureus persistent nasal carriers were defined by an index of carriage greater than or equal to 0.8 and S. aureus intermittent nasal carriers by a positive index of carriage lower than 0.8.
An index of carriage is defined for each patients by the ratio : positive sample/total sample
|
10-week period
|
Collaborators and Investigators
Investigators
- Principal Investigator: Florence Grattard, CHU Saint-Etienne
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1108059
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Staphylococcal Infections
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
GlaxoSmithKlineCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedStaphylococcal InfectionUnited States
-
Merck Sharp & Dohme LLCCompletedStaphylococcal Infection
-
National Institute of Allergy and Infectious Diseases...CompletedStaphylococcal InfectionUnited States
-
Destiny Pharma PlcCompletedStaphylococcal InfectionUnited Kingdom
-
Assistance Publique - Hôpitaux de ParisCompletedMethicillin-resistant Staphylococcal InfectionsFrance
-
National Institute of Allergy and Infectious Diseases...TerminatedStaphylococcal Aureus Infection | Recurrent Staphylococcal Infection | Invasive Staphylococcal InfectionUnited States
-
Aaron ChenJohns Hopkins University; Thrasher Research FundCompletedStaphylococcal Skin Infection | Abscess | Staphylococcal Infection | FolliculitisUnited States
-
Nantes University HospitalCompleted
Clinical Trials on Staphylococcus aureus carriage
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Nantes University HospitalCompleted
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Jiangsu Province Centers for Disease Control and...Third Military Medical University; Chengdu Olymvax Biopharmaceuticals Inc.CompletedStaphylococcus Aureus InfectionChina
-
Jiangsu Province Centers for Disease Control and...Third Military Medical University; Chengdu Olymvax Biopharmaceuticals Inc.CompletedStaphylococcus Aureus InfectionChina
-
Jiangsu Province Centers for Disease Control and...Chengdu Olymvax Biopharmaceuticals Inc.; PLA Army Medical UniversityCompletedStaphylococcus Aureus InfectionChina
-
PfizerCompletedStaphylococcal InfectionsJapan
-
Pherecydes PharmaRecruitingInfection of Total Hip Joint Prosthesis | Infection of Total Knee Joint ProsthesisFrance
-
AbbVieRecruitingIrritable Bowel SyndromeUnited States, Canada, Poland, United Kingdom, Hungary, Bulgaria, Netherlands
-
University Of PerugiaTerminated